The Trump administration announced deals on Thursday with pharmaceutical giants Novo Nordisk and Eli Lilly that would lower the cost of GLP-1 drugs for many Americans, including those on Medicare.
Lawmakers at the helm of the Senate Special Committee on Aging have proposed a sweeping series of changes that could transform the way the government safeguards the quality of essential generic drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback